Integrating 3D printing technologies into microfluidic device fabrication has significantly advanced the field. Rapid prototyping and complex geometries are not easily achieved with traditional methods like soft lithography. Stereolithography (SLA) and two-photon polymerization can create exact, intricate microfluidic structures. Despite these advancements, challenges remain, particularly concerning material properties. Many 3D-printed materials lack the optical transparency and biocompatibility essential for biological applications. Requirements for higher-resolution for next-generation microfluidics continues to be a hurdle. To explore these developments further, 3DHEALS welcomes you to join our virtual event focusing on “Microfluidic Devices and 3D Printing” on April 17, 2025. This event gathers industry experts, scientists, designers, and entrepreneurs to provide insights into the latest trends and developments in the field. For more details and registration information, please visit the 3DHEALS events page.
Hemdeep brings over 30 years of business and entrepreneurial experience to his role as co-founder of CADWorks3D. An early adopter of 3D printing (2009), he recognized the waves 3D printing would make for manufacturing processes across various industries – and he knew he needed to be part of this movement. With a background in Physics and Astronomy, when he discovered the applications of 3D printing in scientific fields, particularly in microfluidics, the path was paved.
A mechanical engineer with 25 years professional experience, Paul has been involved in the Life Science sector for the last 10. He founded Rapid Fluidics in 2020 to provide a genuine rapid-protoype service to the microfluidics sector, based on the development of the process to meet the unmet need that he had experienced.
Chris Moraes is a hybrid engineer: he trained in nanoengineering (B.A.Sc.), and switched into mechanical and biomedical engineering (Ph.D, U. Toronto) before holding a Banting / NSERC postdoctoral fellowship at the University of Michigan’s Biointerfaces Institute. His research interests lie at the interface between engineering, biology and medicine, and he is particularly curious about the role microenvironmental biomechanical forces play in driving disease and development.
Jeff Schultz, co-founder of Phase, has more than 20 years’ experience developing novel 3D printing techniques for a wide range of applications. Now, with the support of 3 NIH grants, Schultz is focusing on developing a novel way to 3D print microfluidics to make organ-on-a-chip models more commercially applicable and accessible.
He earned his Ph.D., M.S., and B.S. in materials engineering from Virginia Tech, where his research focused on understanding the ranges of physical, rheologic and thermodynamic properties that made a polymer suitable for selective laser sintering additive manufacturing. Schultz then became a principal partner in a start-up 3D-printing company which developed metal additive manufacturing technology and aerodynamics instrumentation. There, he led technology development and was the first inventor on all the key patents related to its additive friction stir technology. After exiting the company, Schultz earned his MBA from MIT and then built the US additive manufacturing business unit for Oerlikon Corporation, a Swiss industrial conglomerate. The facility he grew and led at Oerlikon was among the largest additive manufacturing component production facilities globally.
After a successful scale-up at Oerlikon, Schultz returned to entrepreneurship and co-founded Phase, his second startup focused on developing additive manufacturing technology. The company has received support from the NIH, NC Biotech, and the State of North Carolina, and has 5 patents in various stages related to its novel 3D printing and VivorrayTM technology.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
3DHEALS is kicking off its first in-person/hybrid event in 2025 in San Francisco, welcoming investors, entrepreneurs, and innovators in the space. The healthcare industry is transforming, driven by 3D printing and bioprinting technologies redefining patient care. This exclusive in-person event offers an opportunity to explore the latest advancements in custom prosthetics, implants, bioprinted tissues, and scaffolds. Engage with top medical professionals, engineers, and industry pioneers in charge of this rapidly growing sector. For investors, this event is a gateway to high-growth opportunities in healthcare and advanced manufacturing. With global demand for personalized medical solutions rising, 3D printing is set to disrupt traditional supply chains and unlock new revenue streams. Connect with startup founders, industry executives, and R&D leaders driving the commercialization of these technologies. Whether you’re looking to fund the next breakthrough or gain strategic insights into this expanding market, this is an event you won’t want to miss. Secure your place today.
Implants & medical technologies sales leader with an emphasis in spinal endoscopy, previously focused on open spine procedures, joint reconstruction, thoracic oncology, and biologics. Currently employed with Arthrex in the spinal endoscopy division. Spinal endoscopy is the most minimally invasive surgical procedure for neural decompression surgery.
Formerly employed with Anatomics as Senior Product Specialist with work involving groundbreaking patient-specific implants mostly for oncology use.
Dr. Mahadik received his PhD in Chemical and Biomolecule Engineering at the University of Illinois at Urbana Champaign. His expertise is in the field of tissue engineering, stem cell biology and 3D printing. He was the Assistant Director at the NIH Center for Engineering Complex Tissues (CECT) at the University of Maryland that focused on novel applications of 3D printing and bioreactor technologies. Presently, he is the Director of Research at Prellis Biologics with a focus on using 3D Lymph Node Organoids for the development of new clinically relevant antibodies.
He shares a deep interest in Regenerative Medicine and its applications in the clinical space, ranging from implantable scaffolds for repair and regeneration, to the development and assessment of new therapies using complex in vitro models that recreate native biology.
Rajan Patel has over three decades of expertise in driving innovation and advancing commercialization in the healthcare industry. His extensive background encompasses diagnostics, critical care, patient monitoring, and drug delivery technologies. At iO Life Science and iO Life Ventures, he leads the incubation of transformative technologies, overseeing a diverse portfolio of over 20 startups. With significant investment experience and a strong commitment to fostering progress in healthcare, Rajan has played a pivotal role in accelerating the development and commercialization of innovative medical devices. His leadership contributions span renowned companies such as MiniMed, Heartport, Aerogen, M2 Medical, and Cirtec Medical.
As the CEO of Kallisio, Rajan is at the forefront of advancing patient-specific medical devices, addressing key side effects of cancer therapy, such as oral mucositis and other oncology-related complications. Kallisio is dedicated to driving personalized medicine through innovative solutions that enhance treatment precision and improve patient outcomes. These technologies reflect Kallisio’s broader mission to mitigate the adverse effects of cancer therapy, equipping clinicians with tools to deliver precise, effective, and patient-centered care.
Kuan-Lin Chen
Dr. Kuan Lin Chen is an orthopaedic surgeon specializing in hip and knee replacement, as well as complex joint reconstruction following musculoskeletal tumor resection. He also serves as a medical advisor at AMED Ventures. With a background in bioengineering from UC Berkeley, he has a strong foundation in medical device design and innovation. In addition to his clinical and advisory roles, he actively lectures at universities on strategic design thinking in medical technology.
A prolific innovator, Dr. Chen holds several patents and made history as the first resident doctor to license technology from his home academic institution to a company. His passion for bridging clinical needs with cutting-edge solutions led him to his advisory role at a Medtech venture group in the Bay Area, where he provides evidence-based analysis to drive investment and development strategies.
Jesse Courtier, is a Healthcare Investor, Entrepreneur, and Pediatric Radiologist. He is current Managing Partner of Healthcare GT Ventures, a new Venture Studio/Venture Platform. He founded Sira Medical, a venture backed UCSF spinout using Augmented Reality for pre-surgical planning and worked to bring this from idea to FDA 510k cleared application. His interests lie in the application of innovative technologies that positively impact patient lives and improve physician workflow efficiency and well-being.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
Design for medical 3D printing is not just new software. It reinvents the current design thinking behind medical device innovations, removing many traditional manufacturing constraints. 3D printing (earlier also known as rapid prototyping) is particularly complementary to design thinking, where an iterative approach is required to solve complex problems. Also, unlike conventional methods, 3D printing allows for unprecedented customization and precision, enabling the creation of devices more tailored to individual patients’ specific anatomy or needs, which are typically more costly and sometimes even impossible with traditional manufacturing processes. In this virtual event, we aim to bring together the most active 3D printing software providers, engineers, and medical 3D printing designers to share their insights and updates on our existing toolkits for medical 3D printing design, best cost-effective practices, and future growth areas. We invite everyone motivated to learn, network, and collaborate in future medical innovations to join this critical (and brainy) conversation.
Apply to speak or sponsor the event: info@3dheals.com
Dr. Elissa Ross is a mathematician and the CEO of Toronto-based startup Metafold 3D. Metafold makes a 3D geometry toolkit to solve design, simulation, automation and commercialization challenges in digital manufacturing. Metafold supports innovators to produce highly distinctive products, including lightweight parts for aerospace, cell scaffolds for lab-grown meat, and running shoes that accelerate athletes. Elissa holds a PhD in discrete geometry (2011), and worked as an industrial geometry consultant for the 8 years prior to cofounding Metafold. Metafold is the result of observations made in the consulting context about the challenges and opportunities of additive manufacturing. Drawing on her background in mathematics and industrial consulting, Elissa focuses on leveraging geometric principles to enhance product performance through computational design.
Dr. Paul Egan is a tenure-track assistant professor in the Department of Mechanical Engineering at Texas Tech University and leads the Medicine, Mechanics, and Manufacturing Design (M3D) Lab. The M3D Lab investigates a unique integration of engineering design methods for system modelling, optimization, and experimentation of diverse biomedical systems using computational design and additive manufacturing approaches. Research applications focus on 3D printing for tissue scaffolds, personalized nutrition, prosthetics, and medical devices. Dr. Egan’s engineering design teachings promote mechanical design innovation for positive societal impacts, which aligns with Dr. Egan’s leadership in entrepreneurial activities and medical technology start-ups.
Dr. Jade Myers is the Research Development Specialist at the AMPrint Center and Adjunct Faculty within the departments of Biomedical Engineering, Industrial and Systems Engineering, and the School of Individualized Studies at the Rochester Institute of Technology (RIT). She has served as Research & Development Associate and Haiti Project Team Lead for LimbForge, a non-profit organization specializing in increasing access to quality upper limb prostheses for underserved communities throughout the world and has collaborated with Doctors without Borders (MSF) on multiple international low-cost medical device projects involving 3D printing. She instructs several graduate and undergraduate courses related to medical device design including “3D-Technologies for Prosthetic Applications”—an interdisciplinary project-based class that leverages 3D-printing, scanning, and CAD to engage students in the many facets of prosthesis design— and “Personalized 3D Printing” in which students use CT scan and point cloud data in the design of person-specific medical and athletic devices. She earned a PhD in Mechanical and Industrial Engineering in 2023, and her current research centers on finding novel ways to improve the design and safety of printed prosthetic sockets using density-graded lattice structures. She was the recipient of the 2023 Orthotic and Prosthetic Education and Research Foundation (OPERF) fellowship, and her work placed third in the international nTopology/EOS Responsible Parts Challenge competition among submissions from 28 colleges and universities across 16 countries. She received the 2023 Bruce R. James Distinguished Public Service Award for her prosthetics-related work in low-resource countries.
Mandy is a Senior Solutions Engineer at nTop and has supported customers with the nTop CS team for over three years. She trains and advises customers on simulation, topology optimization, latticing, automation, and field-driven design. She has experience in additive design, CAD, 3D printing, and machining, and she graduated with a BS in Mechanical Engineering from Tufts University. She currently lives in the Boston area and is the Boston Ambassador for Women in 3D Printing.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
Integrating 3D printing and biofabrication in breast implants and reconstruction represents a significant innovation in medical technology. Using biocompatible materials and advanced printing techniques, these implants can be customized to match the unique anatomical features of each patient. Unlike traditional implants, biofabricated breast implants have the potential to mimic natural tissue more closely, reducing complications and improving aesthetic outcomes. This technology also allows for the incorporation of living cells, which could enable the regeneration of breast tissue, offering a groundbreaking approach to reconstructive and cosmetic surgery. The convergence of 3D printing and biofabrication is poised to revolutionize the future of breast augmentation and reconstruction.
Mohit P. Chhaya, PhD, is a biomedical engineer with a career marked by pioneering contributions to biofabrication and tissue engineering. A Queensland University of Technology alum, Dr. Chhaya has authored numerous Q1 top-tier journal publications and developed cutting-edge technologies licensed by leading 3D BioPrinter manufacturers. As the co-founder and CEO of BellaSeno, he successfully raised EUR 17 million, steering the company towards ISO 13485 certification and steering its flagship product, Senella, through clinical translation. His tenure at BellaSeno also involved transforming it into a multi-product company and achieving market authorization for innovative best-in-class regenerative scaffolds. Before founding BellaSeno, Dr. Chhaya co-founded Biofabrication Design Solutions, focusing on additive manufacturing for multi-material constructs. His professional journey includes roles in regulatory affairs, postdoctoral research, and financial analysis, demonstrating a broad skill set beyond bioengineering. Dr. Chhaya’s innovations have garnered international recognition, earning him prestigious awards such as the MIT Top 20 Innovators Under 35 and the German Innovation Award 2021. An active member of the ASTM Committee on Additive Manufacturing and a respected speaker at international conferences, Dr. Chhaya is deeply involved in advancing biofabrication standards and education. His remarkable IP portfolio includes numerous patents and designs across various jurisdictions, underscoring his contribution to medical technology innovation.
Julien Payen is a Biomaterials Engineer who began his career with contributions to respiratory devices by working on nanofibers development for air filtration. Then he worked successively as R&D manager for a multinational company in protective devices and in the finance of innovative projects in medical devices. He founded Lattice Medical in late 2017 with two medical doctors and a plastic surgeon to bring an alternative to the breast reconstruction landscape with a 3D printed and bioabsorbable implant, MATTISSE. He successfully raised EUR 20 million with Lattice Medical, gathering a team of 25 engineers, PhDs and complete successful milestones such as ISO 13485:2016 certification, the establishment of a 3D printing farm production facility in a clean room to produce our devices and bringing their lead product MATTISSE, through clinical trials. Thanks to his impetus, he has enabled Lattice Medical to become a medical company developing several medical products (breast: MATTISSE, skin: RODIN) as well as medical-grade raw materials for 3D printing (LATTICE SERVICES). He has earned several awards such as Start-Up of the year by the Challenges magazine in France or apart of Medtech Innovator cohort 2024 or nominee of the prestigious Galien Prize in New York in 2023.
Dr. Jeong Hun Park is a Research Scientist in the Wallace H. Coulter Department of Biomedical Engineering and Center for 3D Medical Fabrication at Georgia Institute of Technology and Emory University. Since starting his academic career as a Research Scientist I in 2019, Dr. Park has performed various research focusing on the development of advanced functional medical devices using 3D bioprinting and biomechanics for a wide range of biomedical applications, including tissue engineering, disease treatment, and biomimetic in vitro tissue model for diagnosis.
Dr. Xue Dong is a dedicated researcher specializing in tissue engineering and its applications in surgery. Her interest in the field began as a medical student at Weill Cornell Medical College, where she worked on collagen-based microspheres for prenatal cleft lip repair and dermal substitutes for wound healing. This experience deepened her understanding of scientific inquiry in relation to clinical practice. Since her general surgery residency, Dr. Dong has been focused on breast cancer-related research, addressing challenges faced by patients undergoing surgery and reconstruction. Her work includes evaluating treatment effects through data analysis, optimizing 3D-printed biomaterial scaffolds for reconstruction, and exploring fat grafting techniques for soft tissue enhancement.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
This annual virtual event dedicated to biomaterials and material science for 3D printing implants, medical devices, and biofabrication presents a unique and compelling opportunity for individuals across various disciplines to delve into the cutting-edge advancements shaping the future of healthcare. With the demand for innovative solutions in implantology and tissue engineering on the rise, this event serves as a pivotal platform for researchers, engineers, clinicians, entrepreneurs, and industry professionals to explore the latest breakthroughs and methodologies in biomaterials science. Attendees will have the chance to gain invaluable insights into the development of novel materials, fabrication techniques, and biofunctionalization strategies tailored for applications in 3D printing implants, medical devices, and biofabrication. From elucidating the fundamental properties of biomaterials to showcasing innovative approaches for enhancing biocompatibility, mechanical properties, and bioactivity of implants, this event offers a comprehensive overview of the current state-of-the-art in material science for medical applications. Moreover, the virtual format ensures accessibility to a global audience, facilitating networking opportunities and knowledge exchange among professionals from diverse backgrounds and regions.
An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical, an innovation-based and technology-driven research company, in 2003. The company is focused on developing a wide range of novel absorbable polymeric biomaterials to enhance quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada earned a doctorate in chemistry from the Stevens Institute of Technology in New Jersey and has over 40 years of research experience in the medical device industry, including 20 years of service at Ethicon, Inc. (a Johnson & Johnson Company). While at Ethicon, Dr. Bezwada’s research and development efforts led to the launch of a number of products, including Monocryl®, a new ultra-pliable synthetic absorbable monofilament suture. This product has represented worldwide sales of more than two (2) billion dollars since its launch in 1993 and current annual sales of over 100 million dollars. In recognition of this invention, along with its development, Johnson & Johnson, Inc. awarded Dr. Bezwada the prestigious Johnson Medal in 1996. Dr. Bezwada has been a prolific inventor and has been issued more than 135 U.S. patents on absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters, and controlled release polymers. FDA-approved products such as MONTAGE® Putty, MONTAGE Fast Set Putty, Montage Flowable Putty, and PERMATAGE Putty, marketed by Abyrx for wound healing and bone applications, are based on Bezwada Biomedical’s absorbable polyurethane technology. Dr. Bezwada has also pioneered specialty bio-inks for 3D printing applications. In addition to his passion for science and technical accomplishments, Dr. Bezwada has also established a non-profit organization, Society for Basic Needs, in India. This organization has a mission aimed at improving the quality of life for those less fortunate by providing them with essential amenities and opportunities for health and education.
Dr. Albanna is the founder and CEO of Humabiologics, one of the only regenerative medicine companies focused on developing and commercializing human-derived biomaterials to researchers around the world for regenerative medicine applications. He holds a PhD in Biomedical Engineering, 2 master’s degrees in Materials Sciences and Electrical & Computer Engineering and completed a postdoctoral fellowship at Wake Forest Institute of Regenerative Medicine, where he served as the lead of the skin bioprinting group and is currently an adjunct assistant professor of Surgery at Atrium Health Wake Forest Baptist. Dr. Albanna authored several peer-reviewed papers, book chapters and is the inventor of several issued and patent-pending applications. Dr. Albanna has 15 years of industry experience, during which he has held several senior and executive leadership positions across several industries including medical devices, blood banking, and tissue banking. His work in regenerative medicine was recognized through several prestigious awards including 2013 Thomas Edison Gold Award in Innovation, 2018 Arizona Innovator of the year finalist, and 2021 Arizona Leader in Innovation Award.
As CEO, Anis Hadj Henni oversees Rheolution’s development strategy over the Life Sciences and Agri-Food business units. He is also in charge of the customer experience and key partnerships with strategic business partners, distributors and investors. Anis works closely with Rheolution’s sales, operations and engineering teams to provide the best instruments, software and services to customers. As an entrepreneur, Anis is driven by a powerful purpose: ‘‘My team and I are on the mission of ending the status quo in the analytical testing space that limits our customer’s ability to innovate and create value for the benefit of people’s health and nutrition. We are defining, with our community of users, Soft Matter Analytics as the paradigm that will shape the future of analytical instrumentation. And, because an idea is not enough, we gathered an outstanding and talented team that works hard to make Soft Matter Analytics a realty to our customers and communities’’, he says. After a successful career in research, Anis co-founded Rheolution in 2009 with new ideas and a vision of what the future could look like. A decade after, he is extremely proud of seeing customers, colleagues, business partners and stakeholders sharing, enriching and building that vision. Anis graduated in civil engineering from the National Polytechnic School of Algiers (Algeria) and holds a Ph.D. in mechanics from Université de Bordeaux (France).
Meet Annaliese Vojnich, a dynamic business development and technical sales manager currently overseeing the Puredyne® brand and the Hygienic Solutions division for ViscoTec America. Annaliese’s professional journey spans various industries, including sales, pharmaceuticals, medical technology, research and development, and hygienic FDA manufacturing, equipping her with a versatile skill set that stands at the forefront. Earning a bachelor’s degree in Dietetics/Nutritional Sciences from the esteemed University of Georgia in 2018, Annaliese’s academic foundation underscores her commitment to knowledge and growth. Her pursuit of education extended further with a Certificate in Women’s Entrepreneurship from Cornell University, where she refined her leadership abilities in 2022. Annaliese’s passion for biotechnology began in 2014 at the Center for Applied Genetic Technologies, a University of Georgia facility. During her time as an assistant lab manager and research assistant, her responsibilities were concentrated on genetic transformation, somatic embryogenesis, plant breeding and genetics, and tissue culture management. Annaliese’s foundation has positioned her to excel not only in sales and management roles but also in bridging the gap between innovation and real-world applications. Her current role at ViscoTec America, where she contributes to cutting-edge dosing technology and bioprinting advancements, showcases her ability to merge her passion for science with her sales acumen.
Ferry Melchels is the research professor of Biomaterials and Tissue Engineering at the Future Industries Institute at the University of South Australia in Adelaide. His main interests lie in polymeric biomaterials for 3D printing, tissue engineering, and drug and vaccine delivery. His work has been published in leading journals, attracting over 17,000 citations. He is a recipient of the Patrick Neill Medal for Early Career Researchers in the Life Sciences from the Royal Society of Edinburgh (2020), and the Mid-Career Investigator Award from the International Society for Biofabrication (2019). Ferry holds an MSc (2005) in chemical engineering and PhD (2010) in biomaterials from the University of Twente (The Netherlands). He was a Marie Curie post-doctoral fellow between two of the pioneering institutes in Biofabrication; Queensland University of Technology (Brisbane, Australia) and University Medical Center Utrecht (The Netherlands) and held his first PI position at Heriot-Watt University in Edinburgh (UK) from 2015-2023. Besides home brewing the best beers on the weekend, his future aim is to continue advancing materials-based technology platforms for biomedical applications.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
Led by clinical and technical experts from major institutions in the US, EU, and Singapore, this event aims to update all stakeholders on everything about point-of-care 3D printing. From personalized surgical tools to anatomical models for preoperative planning, participants will discover how this technology is revolutionizing patient care by bringing manufacturing capabilities directly to the bedside. Speakers and the audience will join a conversation on the current status and future direction of this new way of care delivery.
Shannon Walters is an innovation enabler and workflow optimization enthusiast. At Stanford 3D and Quantitative Imaging Lab, Shannon works closely with healthcare providers, researchers, and educators to enable effective health visualization. Recent innovations are of particular interest to Shannon such as AI in Medical Imaging, Virtual/Augmented Reality, 3D Printing, and longitudinal assessment of complex disease processes.
Chris LeCastillo is the Innovations Manager of the Stanford 3D and Quantitative Imaging Laboratory, where he is a Radiologic Technologist and a Certified Imaging Informatics Professional. He helps drive forward meaningful innovations in 3D printing, medical imaging AI, and manages the XR Neurosurgical Navigation program at Stanford. Chris holds a Bachelor of Science in Health Information Management and a Master of Health Leadership.
Dr. Mark Tan is a Radiologist and the Clinical Lead of the Singapore General Hospital 3D Printing Centre. Dr Tan enjoys working with clinical teams on virtual surgical planning for head and neck, plastic and reconstructive, neurosurgical, oncological, orthopaedic and cardiac surgeries. Dr Tan also enjoys working with clinical teams, imagers, engineers, administrators, academia and industry in designing and producing from medical imaging patient-specific anatomical models for surgical rehearsal and implant sizing, surgical guides for localisation and reconstruction, bespoke orthotics and prosthetics, as well as custom implants, to improve clinical care.
Dr. Neha Sharma, PhD, is the Deputy Head of the Medical Additive Manufacturing (Swiss MAM) Research Group and the 3D Print Lab at University Hospital Basel, Switzerland. With a background in Craniomaxillofacial (CMF) Surgery from India and a PhD in Biomedical Engineering from the University of Basel, Switzerland, Dr. Sharma brings extensive expertise in CMF trauma, reconstructive, and orthognathic surgeries. Her work focuses on integrating digital technologies like medical 3D printing and VR/AR into clinical practice, pioneering computer-assisted virtual surgical planning, and exploring novel biomaterials for reconstructive surgeries.
Brian Overshiner is a distinguished radiation therapist and 3D printing expert with over 20 years of experience in the medical field. His journey into the realm of 3D printing was driven by his passion for technology and innovation. In 2015, Brian spearheaded the creation of the IU Health 3D Innovations Lab, enabling Indiana University Health to become one of the first clinical sites to offer personalized 3D printed radiotherapy treatment devices along with design, prototyping and advanced visualization. Currently, Brian serves as the onsite manager of the Ricoh 3D for Healthcare Innovation Studio in Winston-Salem, NC. This flagship HIPAA compliant, ISO 14485-certified Point of Care 3D medical device manufacturing facility provides immediate access to development, design, and manufacturing services for patient-specific 3D printed anatomical models used in surgical planning and patient education.
This virtual event centered on biofabrication and bioprinting of musculoskeletal tissue. As the demand for effective treatments for bone and cartilage defects continues to rise with an aging population, this event is a vital platform for deep conversations about the challenges, progress, and future of tissue engineering for regenerative purposes in treating orthopedic diseases. By attending, participants will gain invaluable insights into the cutting-edge technologies and methodologies driving the development of innovative treatments for musculoskeletal diseases. Throughout the event, attendees will have the chance to engage with leading experts in the field, who will share their expertise and firsthand experiences in both the scientific and commercialization aspects of the field. Moreover, the virtual format ensures accessibility to a global audience, fostering collaboration and knowledge exchange among professionals from diverse backgrounds and regions. Don’t miss your chance to be part of this transformative event shaping the future of musculoskeletal tissue engineering and regenerative medicine.
Dr. Zhang is an Associate Professor in the Department of Medicine at Harvard Medical School and Associate Bioengineer in the Division of Engineering in Medicine at the Brigham and Women’s Hospital. He is directing the Laboratory of Engineered Living Systems (www.shrikezhang.com), where the research is focused on innovating medical engineering technologies, including 3D bioprinting, organs-on-chips, microfluidics, and bioanalysis, to recreate functional tissues and their biomimetic models, for applications in regenerative medicine and personalized medicine. Dr. Zhang is an author of >330 peer-reviewed publications (>50 covers; citations ~35,000, h-index = 92). His scientific contributions have been recognized by >45 awards.
Dr. Estes received his Ph.D. from Duke University in Biomedical Engineering with an emphasis in chondrogenesis of fat-derived stem cells. Before earning his Ph.D., Brad served as the Manager of Research and Development in the spinal orthopedic division of Medtronic where he oversaw commercialization of medical devices from conception to market, including the achievement of regulatory approval for class III medical devices. He was also integrally involved in seeking intellectual property protection for the innovative products Medtronic was producing. In addition, Dr. Estes has acted as a consultant for both small and large medical device companies. In total, he has over 25 years of industry experience and holds 55 patents associated with medical devices. In his current role, Brad oversees all aspects of CytexOrtho operations with a focus on growth and success. In this position, he provides strategic leadership and sets the vision and direction for the company. His responsibilities include guiding research and development efforts, forging strategic partnerships, securing funding, and ensuring regulatory compliance. Additionally, he plays a hands-on role in fostering a collaborative and dynamic work culture, driving motivation and creativity among the tight-knit team at CytexOrtho.
Dr. Poujade earned her PhD from the University of Hull, UK. During her academic career, she worked on several projects. Including deciphering the roles of growth factors and hypoxia in regulating chondrocytic phenotype in vitro, as well as creating an aorta on a chip model to better understand the mechanisms driving ascending aortic aneurysm. It was after her postdoc at the Karolinska Institute that she joined CELLINK where she now works as Senior Field Application Scientist. As such, over the past 3 years, she has advised numerous researchers on 3D bioprinting techniques and practices to help democratise the fabrication of more realistic research models.
Wilson is a healthcare-focused entrepreneur with a PhD, MPhil, and BEng from the University of Hong Kong, specializing in biomechanics, biomaterials, and bone-related diseases. He also completed technopreneurship training at IECT, University of Cambridge, supported by Dr. Hermann Hauser. In 2014, he founded NOVUS Life Sciences Limited, where he currently serves as Chairman and CEO. NOVUS, a global leader in 3D printing biomaterials, operates cutting-edge manufacturing facilities in Hong Kong and Shenzhen. The company supplies to 35+ countries and 65+ corporate clients, supporting the production of patient-specific implants and devices. Wilson is actively engaged in the startup ecosystem and dedicated to fostering entrepreneurship education. He has been a featured speaker and lecturer at institutions and Bloomberg. Under his leadership, NOVUS has received numerous prestigious awards, including Champion of IMAGINE IF!, CNBC’s hottest startups, and accolades from GIN Austria, French Tech Ticket, and Alibaba Jumpstarter.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
What is the next frontier of medical device and biotech innovation? Don’t miss this upcoming virtual event, “3D Microfabrication 2.0.” Joined by leading experts and pioneers in the field, this event promises to unveil the transformative potential of 3D microfabrication techniques in revolutionizing the landscape of medical device manufacturing. From intricate implants to specialized instruments, participants will gain exclusive insights into how micro or nano-scale 3D printing is reshaping the design, production, and functionality of medical devices with unprecedented precision and efficiency at a micro-scale using a variety of biomaterials. Could bio-chips (microfluidics devices), robotic and endoscopic tips, and microneedles be the next frontier of international technological competition like that for the semiconductor industry? Join the conversation live and find out!
Benjamin Richter is an Application Manager at Nanoscribe and develops microfabrication processes and applications for the life sciences. Before, he completed an interdisciplinary PhD thesis on “Selective Biofunctionalization of 3D Microstructures” in the groups of Prof. Wegener, Prof. Bastmeyer and Prof. Barner-Kowollik at KIT. His scientific papers have been cited more than 1500 times (Google Scholar).
CTO and co-founder of Boston Micro Fabrication (BMF). Chunguan was trained as a mechanical engineer and worked in the semiconductor equipment industry for eight years before starting BMF Precision. Recently, BMF Biotechnology Inc. developed biochips for in vitro drug testing.
Jungho is a Ph.D candidate at Gatech with a background in mechanical engineering. His research is specialized in micro/nanoscale manufacturing. I aim to develop a new metal/polymer additive manufacturing system and generate the processing science for a rapid and cost-effective nanoscale fabrication system.
Talk title, “Scalable printing of metal nanostructures through superluminescent light projection”
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
In-silico simulation refers to using computer modeling and simulations to predict the behavior of biological systems or processes. It is an increasingly important concept for future medical device and drug development. The benefits of in-silico simulation include lowering costs, reducing animal testing, improving accuracy and safety, and clarifying regulatory pathways. This virtual event aims to illuminate the revolutionary potential of in silico simulation in not only 3D printed devices but also medical technology in general and biopharmaceuticals, led by field experts and thought leaders. From drug discovery to medical device design, participants will gain exclusive insights into how computational modeling and simulation reshape the landscape of healthcare innovation. Witness how virtual prototyping and predictive modeling accelerate novel therapies’ development and optimize treatment strategies. This is an event you must not miss.
Dr. Simon Sonntag, CEO & Co-Founder of Virtonomy, has been working in the medical device field for over a decade and has experienced first-hand the challenges of developing and bringing a medical device to market and in clinical practice. Using simulation technology in this field for over ten years now, he has seen the tremendous potential of combining it with digital patient twins – not only to support medical device development but also for the regulatory process and clinical trials. He learned that there is a huge demand from the industry to reduce the time, cost, and risk involved in developing medical products, and these so-called in silico methods can achieve this. Therefore, in 2020 he co-founded Virtonomy with the clear mission to change this industry. Virtonomy stands as a pioneer in the realm of digital patient twins, introducing an end-to-end platform that seamlessly merges real world patient data, artificial intelligence, multiphysics simulations, and predictive analytics to support the medical industry. Virtonomy addresses a significant problem: mitigating the elevated risks, complexities, and time constraints entailed in medical device development, ultimately streamlining the journey to market introduction. Utilizing their advanced technology, they enable medical device developers to conduct product development and testing in the computer, reducing traditional in vivo (animal/human) and in vitro (laboratory) tests with so-called in silico experiments (computer). This makes it possible to explore the interaction of the medical device with physically accurate modeling of the in vitro setup or anatomy of the target population based on real patient data as input. Backed by the FDA and EU Commission, it’s set to cover over 40% of approvals via virtual patients and simulations. The vision of Virtonomy extends to personalized medicine in the future.
American administrative professional with experience in Business Development in Medical Simulation and Marketing of a European Contract Research Organization managing pharmaceutical trials and medical device studies. Twelve years of experience in complex medical/administrative document management in both private and corporate medical offices and metropolitan area hospitals. Currently, she is the business development manager for Simq GmbH.
Dr. Anthony Fejes holds undergraduate degrees in biochemistry and Independent Studies (Bioinformatics) from the University of Waterloo, as well as a Masters degree in Microbiology & Immunology and a PhD in Bioinformatics from the University of British Columbia. Anthony started his science career as the scientific co-founder and Chief Scientific Officer at Zymeworks Inc, before working for companies such as Fabric Genomics and Tenaya Therapeutics in the Bay Area and New York based SolveBio. His experience pairs over 20 years of professional experience as a programmer with a deep background in genomics, biochemistry and data analysis, as well as a decade of management and startup experience. He is CEO and co-founder at HTuO Biosciences.
Dr. Steven Kreuzer is a Senior Managing Engineer at Exponent Inc, a scientific and engineering consulting company, based in the Natick, MA (Boston) office. Dr. Kreuzer received his Ph.D. in Mechanical Engineering from the University of Texas at Austin and has been a consultant with Exponent since 2013. He specializes in stress analysis using both experimental and computational approaches, which include finite element analyses and custom mechanical systems. He has worked with numerous companies and projects, supporting everything from design assessments to analyses and tests supporting regulatory submissions. He has been an active participant in the Living Heart Project with Dassault Systèmes since its inception. He serves as a co-lead of the modeling team on the FDA / Dassault ‘ENRICHMENT’ in silico clinical trial. Dr. Kreuzer has applied his expertise to numerous domains, including electronics, aerospace, energy storage, and biomedical applications.
Dr. Péter Endre Éltes is a board-certified spine surgeon who has authored over 30 scientific publications and supervised multiple medical and engineering students throughout his academic career. He has been devoted to biomechanical research and clinical practice at the National Center for Spinal Disorders in Budapest, Hungary. In 2018, Dr. Éltes co-founded and has since led the In Silico Biomechanics Laboratory. Here, he delved into the intricate world of patient-specific spinal care with the vision of establishing novel techniques to enhance the quality of everyday clinical practice. To achieve this, he introduced various cutting-edge technologies such as surgery planning and finite element modeling, all tailored to the individual patient. Additionally, he developed and implemented a workflow to utilize 3D printing for improved patient outcomes.
Zsolt is a passionate 3D printing specialist in titanium 3D Printing and surface treatment. Zsolt is co-founder and Managing Director of PREMET, a 3D-printing-focused innovative medical device producer. PREMET specialises in the manufacturing of dental products and custom-made human and veterinary implants. It puts a high emphasis on R&D, covering all steps of production, and has been involved in several international projects. PREMET pays special attention to tests and simulations, including in-silico simulations. PREMET has ISO 9001 and ISO 13485 certifications. In addition to his professional activities, Zsolt plays a leading role in different organizations. He is a Community Manager at 3DHEALS, co-founder and Vice President of the Hungarian Additive Technology Association, and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited Med Tech cluster. In MediKlaszter, he also acts as Director of International Relations. Zsolt also has sound experience in preparing and implementing international R&D and capacity-building projects.
Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
